StockData
Alto Neuroscience, Inc. logo

Alto Neuroscience, Inc. (ANRO) stock

ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$25.91+1.00 (+4.01%)

Close on Nov 18, 2026Market cap $1.02BP/E –Yield –

Alto Neuroscience operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Alto Neuroscience's operating income for the twelve months ending Sep 30, 2026 was -$100.55M. For fiscal 2025 it was -$66.36M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$66.36M–
FY2024Dec 31, 2024-$68.61M–
FY2023Dec 31, 2023-$37.81M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$27.23M–
Q2 FY2026Jun 30, 2026-$29.13M–
Q1 FY2026Mar 31, 2026-$27.14M–
Q4 FY2025Dec 31, 2025-$17.06M–
Q3 FY2025Sep 30, 2025-$14.95M–
Q2 FY2025Jun 30, 2025-$18.68M–
Q1 FY2025Mar 31, 2025-$15.68M–
Q4 FY2024Dec 31, 2024-$17.00M–
Q3 FY2024Sep 30, 2024-$18.89M–
Q2 FY2024Jun 30, 2024-$18.34M–
Q1 FY2024Mar 31, 2024-$14.39M–
Q4 FY2023Dec 31, 2023-$11.77M–
Q3 FY2023Sep 30, 2023-$9.72M–
Q2 FY2023Jun 30, 2023-$9.13M–
Q1 FY2023Mar 31, 2023-$7.20M–

More Alto Neuroscience figures

See a number that looks wrong?